Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders

Azacitidine (AZA) for higher risk MDS patients is a standard therapy with limited durability. To monitor mutation dynamics during AZA therapy we utilized massive parallel sequencing of 54 genes previously associated with MDS/AML pathogenesis. Serial sampling before and during AZA therapy of 38 patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Polgarova, Kamila, Vargova, Karina, Kulvait, Vojtech, Dusilkova, Nina, Minarik, Lubomir, Zemanova, Zuzana, Pesta, Michal, Jonasova, Anna, Stopka, Tomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762372/
https://www.ncbi.nlm.nih.gov/pubmed/29340104
http://dx.doi.org/10.18632/oncotarget.22957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762372/
https://www.ncbi.nlm.nih.gov/pubmed/29340104
http://dx.doi.org/10.18632/oncotarget.22957

Ejemplares similares